



COVID-19 Vaccine 3<sup>rd</sup> Dose  
Lakeridge Health Specialty Program (Durham Public Health Unit)  
Patient Referral Form

- **Once completed fax page 1 only to 905-721-4876; the clinic will contact the patient to schedule an appointment**
- Walk-in patients with the form in hand will not be accepted; the form must be faxed by the primary care provider/specialist office

Date: \_\_\_\_\_

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Health Card Number: \_\_\_\_\_ Pt Phone Number: \_\_\_\_\_

Pt email address (if avail): \_\_\_\_\_

**Patient Eligibility:**

Please identify the relevant sub-category below of patient eligibility for a 3<sup>rd</sup> dose of the COVID-19 vaccine:

- Individuals receiving active treatment (e.g., chemotherapy, targeted therapies, immunotherapy) for solid tumour or hematologic malignancies.
- Recipients of solid-organ transplant and taking immunosuppressive therapy
- Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy).
- Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).
- Individuals with acquired immunodeficiency syndrome (AIDS)
- Individuals receiving active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (refer to the 2 CIG for suggested definition of high dose steroids), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive.

**Patient-Specific Treatment Considerations:**

Please note: 3<sup>rd</sup> dose vaccinations are recommended 8 weeks (or 56 days) after second dose.

- No treatment considerations
- Yes, treatment must be considered. Specific scheduling requirements:

\_\_\_\_\_

Prescriber Name & Registration Number: \_\_\_\_\_

Prescriber's contact phone number: \_\_\_\_\_

Signature: \_\_\_\_\_

By signing, I confirm the information above to be true and accurate to the best of my knowledge



**COVID-19 Vaccine 3<sup>rd</sup> Dose**  
**Lakeridge Health Specialty Program (Durham Public Health Unit)**  
**Patient Referral Form**

**CONSENSUS DEFINITIONS FOR CURRENTLY ELIGIBLE PATIENTS**

**Active Treatment for Malignant Hematological Conditions includes:**

Recipients of stable, active treatment (chemotherapy, targeted therapies, immunotherapy) including:

- All malignant hematology patients who are on treatment or who were initially vaccinated during or within 6 months post-treatment (including all CML patients)
- All patients who received an allogenic transplant within the last 3 years prior to their first dose of COVID-19 vaccine or who are on chronic post-transplant immune-suppressive therapy
- All patients who received an autologous transplant within the two years prior to their first dose of COVID-19 vaccine
- All patients who have ever received CART-cell therapy

**Also Eligible:**

- Patients who were initially vaccinated during or within 12 months after treatment with anti-CD20 agents (e.g., rituximab, ocrelizumab, ofatumumab)